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Abstract
Chemoradiotherapy has been a key treatment paradigm in cancer management. One of the main 
research objectives in cancer research has been to identify agents and strategies to improve the 
therapeutic index of chemoradiation. Recent development of nanoparticle (NP)-based 
chemotherapeutics offers a unique opportunity to improve the delivery of chemotherapy, which 
can in turn improve chemoradiotherapy’s efficacy while lowering toxicity. NP-based 
chemotherapeutics also possess several characteristics that are well suited for chemoradiotherapy. 
Therefore, NP chemotherapeutics hold high potential in improving the therapeutic index of 
chemoradiotherapy. This manuscript reviews the NP properties that are favorable for 
chemoradiation and the rationale to utilize nanotherapeutics in chemoradiation. This review also 
discusses the preclinical and clinical data on using NP therapeutics in chemoradiotherapy.
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Introduction
Nanoparticle (NP) therapeutics are increasingly under investigation and development for 
cancer treatment (1). NPs possess unique properties, such as preferential accumulation in 
tumors and low distribution in normal tissue, making them ideally suited for the treatment of 
tumors. While current preclinical and clinical investigations on NP chemotherapeutics have 
focused on systemic treatment, a key application of these drugs lies in improving 
chemoradiotherapy. Chemoradiotherapy has been an important treatment paradigm in 
oncology. While it has improved survival and disease control, chemoradiotherapy also has 
significantly higher toxicities when compared to sequential treatment or either treatment 
alone (2-5). Therefore, there has been strong interest in improving the therapeutic ratio of 
chemoradiotherapy. One strategy is to improve the delivery of chemotherapy to the tumors 
while reducing dose to normal tissue. Unfortunately, previous efforts using traditional drug 
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delivery techniques have not been successful (6). However, the recent development of 
carriers for NP drug delivery offers a unique opportunity. Not only is the biodistribution of 
NPs well-suited for chemoradiotherapy, their controlled drug release property has the 
potential to increase the synergy between chemotherapy and radiotherapy, further enhancing 
therapeutic efficacy. In this review, we will discuss the importance of chemoradiotherapy, 
why NP therapeutics hold high potential in improving chemoradiotherapy, and preclinical 
and clinical studies that have evaluated NP therapeutics in chemoradiotherapy.
The chemoradiotherapy paradigm
Over the last three decades, the concurrent administration of chemotherapy and 
radiotherapy, also called chemoradiotherapy, has emerged as an important treatment 
paradigm in the curative management of many solid tumors (2). The origin of 
chemoradiotherapy dates back to 1970s when Nigro and colleagues demonstrated that 
concurrent radiotherapy and chemotherapy (mitomycin C and 5-fluorouracil) can cure anal 
cancer without the need for surgery (7). This observation led to the evaluation of 
chemoradiotherapy for many other cancers. Today, it is part of the standard of care for many 
difficult to treat cancers, including brain, head and neck, esophageal, gastric, pancreatic, 
small cell and non-small cell lung, rectal, bladder, anal, vulvar and cervical cancers 
(2-5,8-14). In chemoradiotherapy, systemically administered chemotherapy not only 
addresses the potential distant micrometastatic cancers, but also acts synergistically with 
local radiotherapy to improve the therapeutic efficacy against the primary tumor (2). 
Because of this synergistic effect, chemoradiotherapy has not only consistently shown 
improved local tumor control but also improves the rates of cancer cure when compared to 
either sequential treatment or sole administration of chemotherapy or radiotherapy in large 
randomized clinical trials (2,3). Furthermore, chemoradiotherapy also allows the sparing of 
normal organs and omission of surgery in the management of head and neck, anal, bladder 
and cervical cancers (5,11-14). These organ-sparing approaches have significantly improved 
the quality of life of cancer patients. Lastly, chemoradiotherapy can also cure patients with 
esophageal and non-small cell lung cancers who are ineligible for surgical resection due to 
poor general health (10).
Despite the success of chemoradiotherapy, it is not without limitations. Chemoradiotherapy 
cannot always eradicate the primary tumor, especially in diseases such as pancreatic cancer. 
The addition of chemotherapy to radiotherapy has not been able to reduce the dose of 
radiation needed to achieve high probability of cure. The concurrent use of both 
chemotherapy and radiotherapy has also significantly increased the toxicity profile of cancer 
treatment (4,5). Such toxicity has prevented many patients who have poor general health 
from pursuing chemoradiotherapy. Therefore, there is a need to improve the therapeutic 
ratio of chemoradiotherapy. This can be accomplished by either increasing the therapeutic 
efficacy, lowering the toxicity of chemoradiation, or both.
Current approaches to improving the therapeutic index of chemoradiotherapy generally 
involve the incorporation of molecularly targeted agents. Molecularly targeted agents, such 
as bevacizumab and cetuximab, have been evaluated in chemoradiotherapy in rectal cancer 
and head and neck cancer, respectively (15,16). The addition of bevacizumab to 
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chemoradiotherapy for rectal cancer has not shown significant improvement in pathological 
response or survival. In head and neck cancer, the addition of cetuximab to platinum-based 
chemoradiotherapy did not improve clinical outcome (17). Thus, there is a strong need for 
novel approaches and the development of more effective agents that can improve the 
therapeutic ratio of chemoradiotherapy.
NP properties that are uniquely suited for chemoradiotherapy
NP therapeutic carriers possess several important characteristics that are well-suited for the 
delivery of agents to improve chemoradiotherapy.
The enhanced permeability and retention (EPR) effect
NPs preferentially accumulate in tumors through the EPR effect, leading to high 
intratumoral drug concentrations (18,19). Tumor vasculature is generally disorganized, with 
aberrant branching and leaky walls (20-25). Tumor angiogenesis results in rapid 
proliferation of endothelial cells and decreased number of pericytes, which leads to porous 
and leaky blood vessels. These pores can range from 100 nm to several hundred nanometers 
in diameter, as compared to normal vessel junctions of 5-10 nm (18,21,25). Such large pores 
leads to higher vascular permeability and hydraulic conductivity in tumors, enabling 
macromolecules such as NPs to extravasate into tumor interstium (20,21). In normal tissue, 
macromolecules can be effectively cleared by the lymphatic system. However, tumors have 
impaired and inefficient lymphatics, which in turn causes the accumulation of NPs. This 
combination of enhanced of irregular tumor vasculature structure, high vascular density 
within the tumor, increased tumor vessel permeability, and defective lymphatic drainage, is 
called the EPR effect (22,24). The effects of high intratumoral drug concentration can be 
further magnified by radiotherapy, which is spatially targeted to the tumor. Lastly, 
radiotherapy can also enhance the effects of EPR, leading to more preferential accumulation 
of NPs at the tumor. Several preclinical studies have shown that NP accumulation is higher 
in irradiated tumors than non-irradiated tumors (26,27). Thus, NP chemotherapeutics can 
improve the therapeutic efficacy of chemoradiotherapy, with the potential for higher rates of 
complete response (CR) and survival. Moreover, a significant increase in therapeutic 
efficacy can lead to reductions in radiotherapy and chemotherapy doses, which in turn can 
reduce treatment toxicity.
Unique biodistribution of NP therapeutics
The unique biodistribution of NP therapeutics differs from that of small molecule drugs and 
is favorable to application in chemoradiation. Due to their macromolecule size, NPs are 
unable to penetrate normal vasculature and capillaries. Therefore, NP chemotherapeutics 
generally lead to lower drug dose to normal tissues such as skin, lung, and heart when 
compared to their small molecule counterparts (22). Given that most of the toxicity from 
chemoradiotherapy is the result of normal tissue receiving chemotherapy and radiotherapy, 
the lower drug concentrations in normal tissue provided by NPs can significantly reduce 
treatment toxicity. Unlike conventional chemotherapy agents that are cleared via multiple 
routes of excretion from the body, NPs are mainly removed from the circulation via the 
mononuclear phagocytic system (MPS) and hepatic excretion (28). MPS processing 
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(formerly known as the reticuloendothelial system) may lead to the excretion of NPs in bile 
or accumulation within the Kupffer cells of the liver and macrophages in the spleen (28,29). 
The distinctive properties of NP accumulation and clearance enhance the therapeutic ratio 
by reducing the amount of systemic toxicity experienced compared to small molecule 
therapeutics (30).
The advantages of NP biodistribution are illustrated in Figure 1. Using chemoradiotherapy 
for non-small-cell lung cancer (NSCLC) as an example, radiotherapy is aimed at the primary 
tumor and areas that may harbor macro- and micrometastatic cancers (clinical target volume 
or CTV). A larger volume of normal tissue is given a significant dose of radiation due to 
entry and exit of radiation beams and to compensate for motion during treatment of these 
areas. Since systemically administered small molecule drugs distribute widely in normal 
organs and tumors, the normal tissue that receives both chemotherapy and radiotherapy can 
lead to significant toxicities. In contrast, NP therapeutics will mostly concentrate within 
tumors, leading to improved therapeutic efficacy and lower toxicity.
NP pharmacokinetics and controlled drug release
The pharmacokinetics and drug release properties of NP therapeutics are also favorable for 
chemoradiotherapy. In general, NPs have longer circulation half-lives and provide higher 
drug exposure than their small molecule counterparts (31,32). For example, BIND-014, a 
NP formulation of docetaxel, has an area under the curve (AUC) that is more than 100 times 
higher than docetaxel at the same dose. In addition, current NP therapeutics under clinical 
investigation, such as CRLX-101 and BIND-014, release their cargo in a controlled, 
sustanied release fashion (31,32). Both increased drug exposure and prolonged drug release 
can increase the synergistic effects between chemotherapy and radiotherapy in tumor cells, 
improving therapeutic efficacy. Increased drug exposure improving chemoradiotherapy has 
been demonstrated in a large randomized phase III clinical trial in chemoradiotherapy for 
rectal cancer (33). Protracted infusional 5-flurouracil (5-FU) improved the therapeutic 
efficacy and survival when compared to bolus 5-FU. Such data suggest that the use of NP 
therapeutics over their small molecule counterparts should have similar effects on 
chemoradiotherapy.
Preclinical and clinical studies evaluating NP therapeutics in 
chemoradiotherapy
Liposomal therapeutics
Liposomal formulations of doxorubicin were the first NP therapeutics that were developed 
for the clinical treatment of cancer (34). Several preclinical studies evaluated the use of 
liposomal doxorubicin in chemoradiotherapy. Harrington et al. were the first to study 
liposomal doxorubicin and liposomal cisplatin with concurrent radiotherapy in a mouse 
xenograft model of head and neck cancer (35). The authors demonstrated that liposomal 
doxorubicin was more effective than doxorubicin in delaying KB tumor growth with both 
single fraction (4.5 or 9 Gy) and fractionated radiotherapy schedules (9 Gy in 3 fractions). In 
the study of liposomal doxorubicin in a murine xenograft model of osteosarcoma, Davies et 
al. also found that liposomal doxorubicin and radiotherapy acted synergistically to enhance 
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the antitumor effect and delay tumor growth (36). Furthermore, the investigators 
demonstrated that radiotherapy improved the biodistribution of liposomal doxorubicin, with 
increased tumor uptake of the drug by a factor of two to four after radiotherapy. Such novel 
findings suggest that the improved distribution is partially responsible for the higher 
therapeutic efficacy of liposomal doxorubicin.
Clinically, liposomal doxorubicin has been evaluated in several early phase clinical trials of 
chemoradiotherapy. Koukourakis and colleagues conducted most of these studies. His group 
first reported a Phase I trial on the use of liposomal doxorubicin (Caelyx) with 
conventionally fractionated radiotherapy for locally advanced NSCLC and head and neck 
cancer (37). In this small study of 30 patients (15 for each disease), the investigators found 
20 mg/m2 of Caelyx was the maximum tolerated dose (MTD) in head and neck cancer 
chemoradiotherapy and 25 mg/m2 was the MTD for NSCLC chemoradiotherapy treatment. 
The dose-limiting toxicities were mucositis for head and neck cancer treatment and 
esophageal toxicity for NSCLC treatment. In a follow-up phase I/II study, patients with 
inoperable (stage IIIb; T3,4-N2,3-M0) NSCLC were enrolled to receive Taxotere, Caelyx 
and radiotherapy (38). Patients were also given amifostine to minimize toxicity. Grade 3 and 
higher esophagitis, which was the dose-limiting toxicity, developed in 9 out of 25 patients 
(36%). The response rates were 40% CR and 87% partial response (PR), which were 
encouraging for further evaluation. In addition to above mentioned studies, liposomal 
formulations of doxorubicin have also been investigated in chemoradiotherapy for head and 
neck cancer, cervical cancer, recurrent breast cancer and bladder cancer. These clinical 
studies are outlined in Table 1 (39-45).
Despite promising results from these small clinical trials, liposomal doxorubicin has not 
been adopted into chemoradiotherapy treatment. One main reason is that small molecule 
doxorubicin has not been utilized in chemoradiotherapy for any cancer treatment. 
Furthermore, while the clinical results from the liposomal doxorubicin are promising, they 
are not far superior to standard chemoradiotherapy regimens. For example, the response 
rates of chemoradiotherapy with liposomal doxorubicin are comparable to that of cisplatin 
with radiotherapy for head and neck cancer.
Liposomal formulations of cisplatin, while not as extensively studied as doxorubicin, have 
also been investigated in a few preclinical and early-phase clinical trials. Nanoliposome 
encapsulated cisplatin was found to have a greater radiosensitizer effect in in vitro A549 
cells and in vivo Lewis lung carcinoma when compared to cisplatin alone (46). The 
liposomal formulation of cisplatin, Lipoplatin, was also assessed in combination with 
radiotherapy for the treatment of F98 glioma orthotopically implanted in Fischer rats. The 
toxicity of the Lipoplatin was significantly less than cisplatin, though unexpectedly there 
was lower tumor uptake of the liposomal formulation. This was not the case for Lipoxal, the 
liposomal formulation of oxaliplatin. Tumor uptake was 2.4-fold more than with the 
liposome-free oxaliplatin (47). Thus, encapsulating platinum compounds in a liposomal 
formulation may allow for improved drug delivery to the tumor and reduction of adverse 
systemic and local effects, thus enhancing the therapeutic ratio and tumor response to 
treatment with chemoradiotherapy.
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Clinical data evaluating liposomal platinum compounds is also emerging. In 20 head and 
neck cancer patients treated at the University of Pennsylvania, Rosenthal et al. evaluated 
liposomal cisplatin as a radiosensitizer concurrent with conventionally fractionated 
radiotherapy. After minimizing transfusion reactions by slowing the infusion rate and 
increasing the dilution of the formulation, the liposomal cisplatin dose was successfully 
escalated, with similar treatment-related toxicities to that of concurrent cisplatin. For 
example, grade 3 skin and mucosal toxicities within the radiation field were minimal, 
occurring in only 1 and 6 patients, respectively. Furthermore, 11 of the 20 patients (55%) 
had an initial CR at the primary tumor site after completing treatment (48). In a study of 12 
patients with locally advanced gastric cancer who received Lipoplatin, 5-fluorouracil and 
concurrent radiation therapy, high CR rates and minor toxicities were also observed. CR 
rates improved from 33% in patients treated with four cycles to 80% in patients treated with 
five cycles of combined chemoradiotherapy with Lipoplatin, though the total number in each 
group was small at six and five patients, respectively. Again, the toxicity experienced was 
comparable with conventional cisplatin, and performance status actually had a net 
improvement at 2 months from the end of treatment (49). As with liposomal doxorubicin, 
the early-phase results of Lipoplatin are encouraging and await validation in larger clinical 
trials.
Polymer drug conjugates
One of the strategies to improve the pharmacokinetics of chemotherapeutics is to conjugate 
them to hydrophilic polymers to increase their circulation time. These drug-polymer 
conjugates can be considered NPs as they are nanometers in size. However, drug-polymer 
conjugates are generally smaller than 10 nm and thus do not possess some of the NP 
properties, such as controlled release, that are mentioned above. Current drug-polymer 
conjugate research has centered around the N-(2-hydroxypropyl) methacrylamide (HPMA) 
polymer and polyethylene glycol (PEG). Several HPMA conjugates, including doxorubicin, 
camptothecin and palictaxel have been evaluated in early phase clinical trials (50). The 
results are encouraging. There have been several preclinical reports studying HPMA drug 
conjugates in chemoradiotherapy. Lammers et al. studied HPMA-doxorubicin and HPMA-
gemcitabine conjugates with radiotherapy in ATI rat prostate carcinoma tumor model (26). 
The investigators found that radiotherapy can increase the tumor accumulation of polymer-
drug conjugates. Moreover, the polymer-drug conjugates functioned synergistically with 
radiotherapy in delaying tumor growth. In a separate report by the same group, the 
investigators showed that radiotherapy can consistently increase the intratumoral 
concentration of HPMA copolymers independent of the tumor model (27). Such 
observations suggested that the improved therapeutic efficacy from nanotherapeutics in 
chemoradiation can be due to both EPR and radiation induced preferential accumulation. 
Another polymer-drug conjugate that has been studied clinically is poly(L-glutamic acid)-
paclitaxel (PG-TXL). It was evaluated preclinically in chemoradiation by Li et al. in mouse 
xenograft model of ovarian cancer (51). PG-TXL was found to act synergistically with 
radiotherapy in controlling tumor growth. This preclinical data lead to two clinical studies 
evaluating PG-TXL as a radiosensitizer. The first study was phase I trial using paclitaxel 
poliglumex with concurrent radiotherapy in esophageal and gastric cancer (52). The 
investigators identified 70 mg/m2/wk as the MTD. In a recently published trial, the 
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investigators studied paclitaxel poliglumex with temozolomide and radiotherapy in high 
grade glioma (53). Unfortunately, combining temozolomide and paclitaxel poliglumex lead 
to high rates and prolonged (5 months) hematologic toxicity. Therefore, the proposed 
treatment regimen is deemed unsafe.
NP albumin-bound paclitaxel
Abraxane, an albumin-bound 130-nm NP containing paclitaxel, is clinically approved for the 
treatment of metastatic breast cancer (54). This NP therapeutic demonstrated an improved 
safety profile and increased efficacy, with a 25% increase in overall response to treatment, 
when compared to paclitaxel alone (55,56). Preclinical data of mice with ovarian or 
mammary carcinomas treated with Abraxane, radiotherapy, or a combination of both, were 
designed to assess antitumor efficacy and normal tissue toxicity. The albumin bound 
paclitaxel improved radiosensitization, lowering the dose to achieve 50% tumor cure from 
54.3 to 35.2 Gy. Significantly, there was no increase in normal tissue toxicity to rapidly and 
slowly proliferating cells. The greatest radioresponsiveness of the tumor to treatment 
occurred when radiation was given two to three days after Abraxane was administered (57). 
Currently, a number of phase III chemoradiotherapy clinical trials in lung, esophageal, head 
and neck, endometrial and cervical cancer are evaluating the concurrent administration of 
Abraxane with radiotherapy.
Polymeric NP drugs
Current clinical and preclinical research efforts on nanotherapeutics have focused on 
polymeric NP platforms. Several polymeric NPs have been evaluated clinically with one 
formulation (Genexol-PM) that’s approved for clinical use (Korea) (58,59). Although none 
of these polymeric NPs have been studied clinically in chemoradiation, there are several 
preclinical studies on this approach. Our group has evaluated Genexol-PM, a polymeric 
micelle formulation of paclitaxel, with external beam radiotherapy in a mouse model of non-
small cell lung cancer (60). Genexol-PM is compared to Taxol at equivalent doses of 
paclitaxel. We found that chemoradiotherapy with Genexol-PM is more effective than that 
with Taxol in vivo. Moreover, the paclitaxel dose in normal mouse lung 6 hours after 
Genexol-PM injection is lower than that of Taxol. Lower paclitaxel dose in normal tissue 
can potentially translate into lower treatment toxicity from chemoradiotherapy. In a similar 
study, Jung et al. studied polymeric NP formuations of paclitaxel and docetaxel with 
radiotherapy in mouse models of non-small cell lung cancer. They observed enhanced 
synergistic effect with reduced survival fraction of A549 cells in vitro and enhanced tumor 
growth delay in vivo in xenograft mice (61). The author’s group also demonstrated increased 
radiosensitization with delivery of a molecular targeted docetaxel NP compared to docetaxel 
alone and NP docetaxel without molecular targeting. Xenograft head and neck cancer mice 
were used as preclinical model, with folate selected as the targeting ligand because the folate 
receptor is often overexpressed in head and neck tumors (62). In addition to the finding that 
NP docetaxel is more effective than docetaxel, we also found that folate-targeted NP 
docetaxel is more effective as a radiosensitizer than non-targeted NP docetaxel. Such results 
suggest that molecular targeting, when combined with NPs, can further improve therapeutic 
ratio of chemoradiotherapy. Currently, there is intense research interest in developing 
Eblan and Wang Page 7






















targeted NPs for cancer treatment (63,64). These preclinical studies support the further 
investigation of Genexol-PM and other polymeric NPs for use in concurrent chemoradiation.
NP delivery of therapeutic radioisotopes
Although nanomedicine research efforts have mainly focused on the delivery of 
chemotherapeutics, there is growing interest in the delivery of therapeutic radioisotopes 
using NPs. Recently, several antibody-radioisotope conjugates have been approved for 
clinical use in cancer (65). Some the studies involving therapeutic radionanoparticles have 
been theoretical and qualitative in nature. Bouchat et al. showed that radioactive NPs with 
~100 Y-90 atoms per NP can substantially increase the biologic effective dose deposited to a 
solid tumor (66). Hrycushko et al. have modeled liposomes tagged with both beta emitters 
Re-186 and Re-188 for the post-surgical treatment of breast cancer, demonstrating this to be 
a viable method of delivering focal radiation (67,68). Recently, Khan et al. demonstrated the 
antitumor effect of dendrimer NPs carrying therapeutic loads of Au-198. In a melanoma 
model, tumors of mice injected with the Au-198 NP decreased in size by 45% compared to 
the untagged NP with no observed toxicity (69). Our own group has described a combined 
modality NP, ChemoRad NP (70). The NP is composed of a polymeric core with a lipid 
monolayer shell. It can encapsulate hydrophobic chemotherapies such as docetaxel and 
chelate therapeutic isotopes such as yttrium. We were able to show that ChemoRad NP 
containing docetaxel and Y-90 is more effective against ovarian cancer than treatments with 
small molecule drugs or NPs containing single agent in a ovarian peritoneal metastasis 
model (71). Another study reported on a liposome particle combining Indium-111 and 
vinorelbine (72). The agent showed antitumor efficacy in mice with colorectal carcinoma 
xenografts. A key concern for this strategy is the potential toxicity on the main clearance 
organ of NPs, the liver. Further preclinical research is needed to validate the safety of 
delivering therapeutic radioisotopes using NPs.
Summary and future directions
NP therapeutics possess several characteristics that are well suited for application in 
chemoradiotherapy. Preclinical studies comparing NP-therapeutics to their small molecule 
counterparts have all shown that NP therapeutics are more effective and potentially less 
toxic. Thus, there is strong preclinical data to support clinical investigations of 
nanotherapeutics in chemoradiation treatment. Existing clinical data evaluating NP 
therapeutics have been conducted with either drugs that are not typically utilized in 
chemoradiation (doxorubicin) or with NP therapeutics that have not successfully completed 
clinical development. Current clinical studies involving the next generation of NP-based 
therapeutics have mainly focused on systemic treatment. Hence, there is a clear need for 
more clinical trials studying these novel drugs in the chemoradiation context. Such clinical 
investigations can facilitate the clinical adoption of NP therapeutics as well as improve the 
current chemoradiation paradigm. There is also a strong need for preclinical research 
studying NP therapeutics for chemoradiation. Such efforts should focus on identifying the 
optimal NP properties, such as size, drug release kinetics and pharmacokinetics for 
applications in chemoradiation. More studies are also needed to identify novel agents, such 
as wortmannin, that can improve the therapeutic ratio of chemoradiation. Such preclinical 
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data can facilitate the clinical development of NP therapeutics specifically for 
chemoradiotherapy application.
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Diagram of chemoradiotherapy for lung cancer with small molecule drugs (A) vs. NPs (B)
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Table 1
Clinical studies of liposomal doxorubicin with chemoradiotherapy
Investigators Patient population Treatment regimen Outcomes Toxicity
Koukourakis et al.,
1999 (35)





NSCLC: 25 (stage IIIB) Caelyx, Docetaxel,
CFRT and Amifostine
CR: 40% (6 of 15) ;
CR/PR: 87% (13 of 15)
Grade 3 Esophagitis: 36%;
Grade 3 Hematologic: 0%
Varveris et al.,
2004 (37)
NSCLC: 9; HNC: 9 Caelyx, Cisplatin
and CFRT
CR: 33% (6 of 18) ;
PR: 55% (10 of 18)
DLT: Grade 3 Mucositis
Koukourakis et al.,
2007 (38)
NSCLC: 31 (stage IIIB-IV) hypoARC, Caelyx,
and Oxaliplatin




NSCLC: 14 (stage IIIB-IV) hypoARC, Caelyx,
and Vinorelbine
PR: 64%; MR: 21%;
SD: 14%
Grade 2 Esophagitis: 43%;







CR: 29%; PR: 71% Grade 3 Myelotoxicity: 21%;
Grade 3 Proctitis: 21%
Koukourakis et al.,
2005 (41)
Breast cancer: 13 hypoARC, Trastuzumab,
Docetaxel, Caelyx
CR: 71%
(5 of 7 chemoresistant)
Nardone et al.,
2012 (42)















Grade 2 Dysuria: 5.5%;
Grade 2 Incontinence: 2.8%;
Grade 1 Frequency: 7.8%
Caelyx, liposomal doxorubicin; CFRT, conventionally fractionated radiotherapy; CCR, clinical complete response; CR, complete response; DLT, 
dose-limiting toxicity; HNC, head and neck cancer; hypoARC, hypofractionated accelerated radiochemotherapy with amifostine cytoprotection; 
LDFRT, low-dose fractionated radiotherapy; MDR, medium-dose rate brachytherapy; MR, minimal response; NSCLC, non-small cell lung cancer; 
PCR, pathologic complete response; PR, partial response; RT, radiotherapy; SD, stable disease
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